Menarini Group Receives Positive CHMP Opinion Recommending EC Approval of ORSERDU庐 (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation
FLORENCE, Italy & NEW YORK--(BUSINESS WIRE)--Jul 21, 2023--The Menarini Group (鈥淢enarini鈥), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics Inc. (鈥淪temline鈥), a wholly-owned subsidiary of the Menarini Group, announced today that the ...

